Board of Directors

Dr. Gallen trained initially in Philosophy (University of Florida) then trained as a Medical Scientist (M.D., Ph.D., Emory), psychiatrist (Stanford) and neurologist (UCSD) then led an innovative career as an academician (The Scripps Research Institute) where his laboratory with great collaborators pioneered the use of Magnetic Source Imaging developing the first clinical indications for the technology, made important scientific discoveries (including the first demonstration of human cerebral plasticity and of the 40 Hz current in man) and acted as a scientific spokesman supporting the NADAQ IPO of BTi. Dr. Gallen then joined Quintiles, rising to Sr. Medical Director, where he drove pivotal trials of several therapeutics that became registered for CNS and other disorders.

Dr. Gallen then became President of the nascent Premier Research Worldwide (PRWW) and with great staff innovated the first use of Remote Data Capture into the Clinical Research Organization (CRO) field, (an approach now circa >95% of CRO data handling globally), introduced Computer Assisted Research and Development (CARD) into clinical research, played a key role in developing the therapeutic that became XYREMTM led PRWW to become a public company through a NASDAQ IPO then grew the company to international status. Dr. Gallen then joined Pharmacia as VP Medical Research where he led CNS development and/or registration of several therapeutics, managed clinical operations for all therapeutic areas in the Americas, played a leadership role in the successful re-engineering of Pharmacia clinical and was promoted to Site Head R&D for the Kalamazoo site.

Dr. Gallen next became VP Clinical Operations at Wyeth where, enabled by great staff and collaborators, he led a transformative reorganization that produced top tier industry performance, created the Alliance for Clinical Excellence (ACE) with Accenture (the first large scale industry movement into use of India for data management), and developed what emerged as the Functional Services Model for managing out-sourcing, now one of the main industry models globally. Dr. Gallen next became CEO of Vancouver-based Neuromed, negotiated a large collaboration with Merck, in-licensed OROS-hydromorphone from Alza, took Neuromed public becoming CEO of Combinatorx and later, as head of R&D, registered EXALGO™. Prior to joining WEX Pharmaceuticals Inc. as CEO, Dr. Gallen was CEO of SK Biopharmaceuticals, the first Western CEO of a major Korean pharmaceutical company, led its fine staff in significant advancement – moving important therapeutics into successful late stage trials and guided the successful re-focusing of its Custom Manufacturing Business.

Dr. Tőke has broad interdisciplinary experience of more than 20 years in translational research with special focus on preclinical/clinical immunotherapy development (on the field of HIV/AIDS, allergy and cancer). Previously, her research team developed Langerhans cell-targeting immunotherapies, nanomedicine delivery systems, pharmaceutically acceptable polymer syntheses (“novel excipient”) and medical device. All of these were applied in clinical drug development. Additionally, she has strong knowledge of FDA regulations, ICH guidelines GMP manufacturing and quality system establishment. Dr. Tőke is a graduate of Budapest University of Technology and Economics, Budapest, Hungary (PhD) and of Babes-Bolyai University, Faculty of Biochemical Engineering, Cluj-Napoca, Romania (MSc).

Mr. Illés is one of the first investors in Treos Bio. Having served as a non-executive director from inception, he joined Treos as Chief Financial Officer in 2018. Mr Illés has over 20 years of experience in technology investments and corporate finance. He was a founding partner of BXR Partners LLP, the in-house investment advisory arm of BXR Group, a leading international private investment group, prior to which he had a ten-year career in investment banking with Credit Suisse First Boston in London.

A British and Hungarian citizen, Mr. Illés holds a M.Sc. degree in Business Administration (First Class Hons) from Corvinus University, Budapest and a CEMS Master degree in International Management.

Peter Kadas is a senior adviser to BXR Partners LLP. He founded and led Credit Suisse First Boston Budapest from 1989 to 1995. In 1995 he co-founded Renaissance Capital in Moscow before moving to MC Securities in London in 1996. From 1997 to 2000 he was CEO of Croesus Central European Corporate Restructuring Fund which he co-founded.

Mr. Kadas then worked in various roles in the UK arm of a predecessor of the BXR Group until 2010. He joined BXR Partners LLP in November 2010 and holds a number of non-executive directorships in BXR Group companies. A British and Canadian citizen, he has a degree in Economics and Politics from the University of Toronto and an MBA from Dartmouth College.

Through the Kadas Family Charitable Foundation, he and his wife Gyongyver Kadas have chosen important causes worldwide, particularly educational institutions and including Dartmouth College, University of Toronto, Oxford University, the London School of Economics and Haifa University. Furthermore, Mr. Kadas is founder and director of the Kadas Prize Foundation, which, working with partners at Cambridge University, CRASSH (the Centre for Research in the Arts, Social Sciences and Humanities) and Cambridge University Press, funds the Nine Dots Prize, an innovative book prize for creative thinking that tackles contemporary societal issues.

Isabel Fox is Head of Third Party Funds at Molten Ventures. Molten Ventures (formerly Draper Esprit), is a prominent European VC investing at Series A and B opportunities with notable investments in Revolut, TrustPilot, UiPath and Transferwise.
Before joining Molten, Isabel was a General Partner at Outsized Ventures focused on Life Sciences and Healthcare. The portfolio includes: Synthace, Hadean, Optellum, Ellipsis, Vital Health, Huma, Mahana Therapeutics, Phenomic AI, Biomage, OxfordVR and many more. Before venture capital, Isabel founded two corporate PR firms focused on the venture ecosystem (two exits), co-founded two software start-ups (one exit) and been an active angel investor in the UK and US. In 2020, Isabel was appointed by UK Research and Innovation to be a member of the main council of Innovate UK, the innovation agency of the United Kingdom.

Ms. Alon currently serves as a Board Member for Vascular Biogenics (VBLT), Phoska Biopharma Pte Ltd., BlueTree Ltd and Moringa Acquisition Corp (MACAU), in addition to serving as a Chairperson for BrainsGate. Previously, Ms. Alon was a General Partner at Pitango Venture Capital, the largest venture capital fund in Israel, where she established and led investments in the life sciences sector and served as a Board member and Chair for multiple companies ultimately acquired by top innovators in the industry. Earlier in her career, Ms. Alon was a Senior Healthcare Analyst on Wall Street, where she held positions of increasing responsibility at both Montgomery Securities and Kidder Peabody. Ms. Alon is the co-founder of several leading non-profit organizations to advance the technological and life sciences ecosystem in Israel, including a Covid-19 relief fund. Ms. Alon received a B.A. in Economics at the Hebrew University, Jerusalem, a M.Sc. at Columbia School of Physicians & Surgeons and an M.B.A. with a focus in Finance at Boston University.

Daniel Hallgarten is a partner of BXR Advisory Partners LLP, an adviser to the BXR group, an international investment group, and leads HGT Management LLP, a multi-family office.

Following a degree in chemistry from the University of Nottingham and a year in research (natural product synthesis), Daniel trained as a chartered accountant specialising in tax with Arthur Andersen & Co. in London and Brussels. He spent ten years as an investment banker first at S.G.Warburg in London and Madrid and, following two years at the European Investment Fund in Luxembourg, UBS Investment Bank in London where he specialised in the telecoms sector. Before working for a predecessor of BXR Advisory Partners, he spent two years helping to run a small software company which was deploying big data and artificial intelligence solutions in the telecom fraud detection space.

He is a non-executive director of Marex Spectron Group (a commodity futures broker) and Food Freshness Technology Holdings (a food technology company) and is a trustee of The Badur Foundation and the Kadas Prize Foundation. He has an honorary doctorate in law from the University of Nottingham.
As well as advising clients with biotech investments, he is also an investor in early-stage biotech companies in his private capacity.